GREENWICH BOTANICALS
Live / Registered — Registered (as of 14 Apr 2020)
What this means for you
Registered since 14 Apr 2020. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79236872
- Registration number
- 6031353
- Mark type
- Stylized text
- Filed
- 24 Apr 2018
- Published for opposition
- 28 Jan 2020
- Registered
- 14 Apr 2020
- Attorney of record
- Michael T. Olsen
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome
Owner
Prosecution history
- 18 Dec 2025 — CHANGE OF NAME/ADDRESS REC'D FROM IB
- 14 Apr 2025 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
- 20 Nov 2021 — NEW REPRESENTATIVE AT IB RECEIVED
- 15 Sept 2021 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 15 Sept 2021 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 15 Sept 2021 — TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
- 15 Sept 2021 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 15 Sept 2021 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 15 Sept 2021 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 05 Sept 2020 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 18 Aug 2020 — FINAL DISPOSITION NOTICE SENT TO IB
- 18 Aug 2020 — FINAL DISPOSITION PROCESSED
- 14 Jul 2020 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 14 Apr 2020 — REGISTERED-PRINCIPAL REGISTER
- 28 Jan 2020 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED